2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5013 CCRL2 x CD3 bispecific antibody shows potent T-cell-mediated cytotoxicity in TP53-mutated myelodysplastic syndrome/acute myeloid leukemia

Booseong Seo, N/A, Brandy Perkins, BS2, Evangeline Watson, MD, PhD3, Xinghan Zeng, MS4, Yuju An, MS5, Yanyan Wang6, Tushar D Nichakawade, PhD7, Bogdan Paun8, Styliani D Karanika, MD9, Suman Paul, PhD, MBBS10, Theodoros Karantanos, MD, PhD11
1 Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
2 Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
3 4. Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
4 Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States, Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, United States
5 Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, United States
6 Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, United States
7 4. Ludwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, United States
8 Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, United States
9 3. Division of Infectious Diseases, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, United States
10 Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, United States
11 Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, United States

Introduction: Patients with TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have poor outcomes due to limited effective therapies. While CD3-engaging bispecific antibodies show activity in this population, target expression on healthy hematopoietic stem and progenitor cells restricts their therapeutic window due to marrow toxicity. We previously identified the atypical chemokine receptor CCRL2 as highly expressed in TP53-mutated MDS/AML with minimal expression in normal hematopoietic progenitors, supporting its potential as a selective therapeutic target. Here, we demonstrate that a novel CCRL2 × CD3 bispecific antibody (CCRL2 BsAb) induces potent T cell–mediated cytotoxicity in TP53-mutated MDS/AML models.  

Methods: The CCRL2 BsAb was engineered as a single-chain diabody (scDb) format combining an anti-CCRL2 scFv with humanized anti-CD3 scFv (clone UCHT1v9). The CCRL2 BsAb was expressed in Chinese hamster ovary cells and purified using Ni-affinity magnetic beads. T-cells were isolated from healthy donor PBMCs and expanded using CD3/CD28 Dynabeads, with purity confirmed by flow cytometry (>95% CD3+). Binding specificity of the CCRL2 BsAB was assessed by flow cytometry using an anti-His-tag secondary antibody conjugated to AF-647 against CD3-expressing HPB-ALL and CCRL2-expressing TF-1 cells. T-cells were co-cultured with target cells, using a panel of TP53-mutant (TF-1, MDS-L, MDS92, K562, F36P, SET2) and isogenic TP53-wild-type (WT) and TP53-knockout (KO) (UKE-1, MV4-11, MOLM-13) cell lines, primary TP53-mutated MDS/AML samples and healthy donor samples at a 1:1 effector:target (E/T) ratio. Cytotoxicity was assessed by luciferase-based viability assays and flow cytometry. Selectivity was tested by treating CCRL2 WT and KO TF-1 and SET2 cells. In vivo activity was tested by injecting a mixture of Luciferase+ parental TF-1 with activated T-cells (2:5 ratio) in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice followed by placement of micro-osmotic pumps filled with CCRL2 BsAb (200 μg/mouse) or PBS. TF-1 burden was monitored by assessment of bioluminescence signal.

Results: SDS-PAGE and size exclusion chromatography confirmed purity and expected molecular weight of the CCRL2 BsAb. CCRL2 BsAb showed robust binding to both CCRL2-expressing TF-1 cells and CD3-expressing HPB-ALL. Treatment with the CCRL2 BsAb resulted in potent dose-dependent cytotoxicity across TP53-mutant cell lines (TF-1, MDS-L, MDS92, K562, F36P, SET2) at the low nanogram/ml range. TP53 KO cell lines showed similar or higher sensitivity to CCRL2 BsAb compared to the relevant WT ones. Treatment of CCRL2 WT and KO cells showed high selectivity against CCRL2-expressing (WT) cells, with an IC50 of 0.18 ng/mL (95% CI 0.14-0.22) in TF-1 WT cells, while KO cells showed minimal death even at 5 ng/mL, confirming CCRL2-dependent, on-target killing. Treatment of primary mononuclear cells (MNCs) or CD34-enriched cells from TP53-mutated MDS/AML bone marrow samples (N=8) with the CCRL2 BsAb demonstrated potent dose-dependent reduction of CD34+ cells percentage at concentrations as low as 0.5 ng/ml. Treatment of MNCs from healthy donors (n=4) with this agent showed only mild to modest reduction of CD34+ and CD34+CD38- cell population at the highest concentration of 5 ng/ml, suggesting only minimal activity against  healthy hematopoietic cells. Treatment of TF-1 xenografts with the CCRL2 BsAb showed prominent reduction of leukemic growth in NSG mice.

Conclusion: Our findings suggest the CCRL2 BsAb as a promising targeted immunotherapy in TP53-mutated MDS/AML. Evaluation of this agent in additional primary samples and patient-derived xenografts, and cytokine analysis to quantitate T-cell activity are ongoing to further characterize the safety and efficacy of this novel bispecific antibody.

Booseong Seo, N/A: No relevant conflicts of interest to declare.